Glenmark Life Sciences LTD IPO: GMP, Issue Size, Issue price

0
63
Glenmark Life Sciences
Rate this post

Glenmark Life Sciences Ltd IPO is all set to make a debut in the stock market with an issue size of 1513.6 Cr. Glenmark Life Sciences Ltd is a leading API manufacturer in India, and it is a subsidiary of Glenmark Pharmaceuticals.   

Glenmark Life Sciences LTD IPO -Overview  

Glenmark Life Sciences Limited IPO Issue Date         27-29 July 2021        
Glenmark Life Sciences Limited IPO Opening Date         27 July 2021        
Glenmark Life Sciences Limited IPO Face Value         INR 2 per share         
Glenmark Life Sciences Limited IPO Price         INR 720 per share        
Glenmark Life Sciences Limited IPO Lot Size         20 Shares        
Issue Size         1,513.60 Cr        
Offer for sale         453.60 Cr     
Issue Type         Book built Issue IPO         
Listing At         BSE, NSE        
QIB Shares Offered           36.97 times        
NII (HNI) Shares         122.54 times        
Company Promoters         Glenmark Pharmaceuticals Limited is the promoter of the company. 
DCX Systems LTD IPO: GMP, Issue Size, Lot size And Important Dates

Glenmark Life Sciences LTD IPO-Tentative Dates         

Glenmark Life Sciences Limited IPO opening date         27 July 2021        
Glenmark Life Sciences Limited IPO closing date         29 July 2021        
Basis of Allotment         3 August 2021        
Initiation of Refunds         4 August 2021        
The credit of Shares to Demat        5 August 2021        
Glenmark Life Sciences Limited IPO Listing Date         6 August 2021        

Glenmark Life Sciences – Industry Overview.        

The Indian API industry is on a high growth trajectory over the past few decades. It has contributed significantly to the global generics market fulfilling 20% of the global demand in generics in terms of volume, making India the largest provider of generic medicines globally. Currently, India has the highest number of USFDA-approved plants outside of the United States as well as 44% of global abbreviated new drug applications (ANDA). Also, ranked third in the world, the Indian bulk drug industry has grown at a CAGR of around 9% over 2016–2020. It is further expected to expand and grow at a CAGR of around 9.6% during 2021–2026, signifying its future potential and evolving global importance. 

Glenmark Life Sciences LTD IPO

Glenmark Life Sciences LTD IPO – Company Overview   

 Glenmark life science is a leading developer and manufacturer of select high-value, non-commoditized active pharmaceutical ingredients (“APIs”) in chronic therapeutic areas, including cardiovascular disease (“CVS”), central nervous system disease (“CNS”), pain management, and diabetes. Glenmark also manufactures and sells APIs for gastrointestinal disorders, anti-infectives, and other therapeutic areas. Glenmark API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which reflect the capability to branch into other high-value products. They have a strong market share in selecting specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonis amide (CNS) and Adapalene (dermatology). also increasingly providing contract development and manufacturing operations(“CDMO”) services to a range of multinational and specialty pharmaceutical companies. 

 Glenmark Life Sciences LTD IPO-Objectives         

  • To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company. 
  • To finance capital expenditure requirements. 
  • To meet general corporate purposes. 

Glenmark Life Sciences LTD IPO – Financial Statements        

Particulars        31-Mar-21      31-Mar-20      31-Mar-19      
Total Assets        19,970.75 17,256.04 14,753.95 
Total Revenue        18,859.76 15,493.03 8,868.65 
Profit After Tax        3,515.81 3,130.98 1,955.92 

Glenmark Life Sciences LTD IPO Strengths        

  • Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management. 
  • Export products in Europe, Latin America, North America, Japan, and the rest of the world. 
  • Strong relationship with leading global generic companies. 
  • Proven track record of strong financial performance. 
  • High-quality product manufacturing with R&D infrastructure. 

Glenmark Life Sciences IPO Weakness         

  • Dependency on a limited number of key customers for a significant portion of its revenue. 
  • Regulatory action due to a manufacturing or quality control room. 

Company Contact Information

Glenmark Life Sciences Limited
Plot No. 170-172, Chandramouli Industrial Estate,
Mohol Bazarpeth, Solapur 413 213,

Phone: +91 2189 234456/ +91 2189
Email: complianceofficer@glenmarklifesciences.com
Websitehttp://www.glenmarklifesciences.com/

Glenmark Life Sciences IPO Registrar



Phone: 04067162222, 04079611000
Email: glenmark.ipo@kfintech.com
Websitehttps://karisma.kfintech.com/

Glenmark Life Sciences IPO Lead Manager(s)

  1. BofA Securities India Limited (Past IPO Performance)
  2. BOB Capital Markets Limited (Past IPO Performance)
  3. DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd) (Past IPO Performance)
  4. Goldman Sachs (India) Securities Private Limited (Past IPO Performance)
  5. Kotak Mahindra Capital Company Limited (Past IPO Performance)
  6. SBI Capital Markets Limited (Past IPO Performance)

LEAVE A REPLY

Please enter your comment!
Please enter your name here